Shopping Cart
- Remove All
- Your shopping cart is currently empty
GSK3532795 (also known as BMS-955176) is a potent oral second-generation HIV-1 maturation inhibitor (MI) that has advanced to phase IIb clinical trials. This compound exhibits broad coverage against polymorphic viruses (EC50 < 15 nM, covering common polymorphisms representing 96.5% of HIV-1 subtype B) and demonstrates favorable pharmacokinetic properties in preclinical species.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | GSK3532795 (also known as BMS-955176) is a potent oral second-generation HIV-1 maturation inhibitor (MI) that has advanced to phase IIb clinical trials. This compound exhibits broad coverage against polymorphic viruses (EC50 < 15 nM, covering common polymorphisms representing 96.5% of HIV-1 subtype B) and demonstrates favorable pharmacokinetic properties in preclinical species. |
Alias | VF90GZ0UQI, BMS-955176 hydrochloride monohydrate |
Molecular Weight | 745.49 |
Formula | C42H65ClN2O5S |
Cas No. | 2023798-97-0 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.